Large-scale in vitro preparation of new gp96 tumor vaccine and analysis of its induction of specific anti-tumor immunoresponses.
- Author:
Xiaoli YAN
1
;
Changfei LI
;
Xiaojun ZHANG
;
Ying JU
;
Bao ZHAO
;
Songdong MENG
Author Information
1. CAS Key Laboratory of Pathogenic Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Cancer Vaccines;
biosynthesis;
genetics;
immunology;
therapeutic use;
Female;
Heat-Shock Proteins;
biosynthesis;
genetics;
immunology;
therapeutic use;
Melanoma, Experimental;
therapy;
Mice;
Mice, Inbred C57BL;
Neoplasm Transplantation;
Recombinant Fusion Proteins;
biosynthesis;
genetics;
immunology;
therapeutic use;
Skin Neoplasms;
therapy;
Yeasts;
genetics;
metabolism
- From:
Chinese Journal of Biotechnology
2011;27(11):1598-1605
- CountryChina
- Language:Chinese
-
Abstract:
Heat shock protein gp96 isolated from tumor tissues holds great promise for tumor immunotherapy. However, at present only very limited amount of gp96 protein can be isolated from tumor tissues. Here, we reconstituted the yeast-expressed gp96 (recombinant gp96, rgp96) with B16.F10 melanoma antigens in vitro to prepare new gp96 tumor vaccine on large-scale, and analyzed its induction of specific anti-tumor immunoresponses by ELISPOT, IFN-gamma intracellular staining and cytotoxicity assays. Immunization with rgp96-tumor antigen complexes significantly inhibited B16 tumor growth compared with either rgp96 or tumor antigens alone and led to enhancement of tumor-specific T-cell activities, which was found similar to that of tumor tissue derived gp96. Our results therefore may provide bases for large-scale preparation of the new generation of gp96 tumor vaccines.
